Skip to main content
. Author manuscript; available in PMC: 2018 Jul 10.
Published in final edited form as: Sci Transl Med. 2017 Jul 12;9(398):eaal5272. doi: 10.1126/scitranslmed.aal5272

Fig. 3. JQ-EZ-05 is a specific and reversible EZH1/2 inhibitor.

Fig. 3

(A) JQ-EZ-05 structure.

(B) Inhibition of recombinant EZH1 and EZH2 by JQ-EZ-05 in vitro.

(C) Immunoblots of CAKI-2 cells treated with 1 μM JQ-EZ-05 for the indicated number of days or treated for 5 days followed by removal (washout) for 1–3 days.

(D) Heatmap displaying gain (red and green) or loss (blue and black) of histone marks in 2 biological replicates (labeled 1 and 2) of CAKI-2 cells treated with the indicated concentrations of JQ-EZ-05 or DMSO vehicle for either 24 hours (D1) or 1 week (D7).